BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+8.77%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$639M
AUM Growth
+$639M
(+5.9%)
Cap. Flow
-$4.36M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
2
Reduced
–
Closed
1
Top Buys
| 1 |
Axon Enterprise
AXON
|
$10.4M |
| 2 |
Lineage Cell Therapeutics
LCTX
|
$5.79M |
| 3 |
AST
Asterias Biotherapeutics Inc. Series A
AST
|
$3.58M |
Top Sells
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$24.1M |
Sector Composition
| 1 | Consumer Staples | 47.49% |
| 2 | Healthcare | 40.87% |
| 3 | Industrials | 1.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monster Beverage
MNST
$60.9B
| $304M | 42.32% | 4,797,408 | – | – |
|
2
STAAR Surgical
STAA
$1.36B
| $168M | 23.45% | 10,855,179 | – | – |
|
|
3
Lineage Cell Therapeutics
LCTX
$267M
| $64.4M | 8.98% | 29,971,561 +2,692,307 | +10% | +$5.79M |
|
4
iShares Russell 2000 ETF
IWM
$67B
| $64M | 8.93% | 420,000 | – | – |
|
|
IMDX
5
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $16.7M | 2.33% | 3,596,680 | – | – |
|
|
AST
6
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $11.9M | 1.66% | 5,292,156 +1,592,308 | +43% | +$3.58M |
|
|
7
Axon Enterprise
AXON
$58.7B
| $10.4M | 1.44% | +391,092 | New | +$10.4M |
|
|
MNK
8
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – | -644,822 | Closed | -$24.1M |
|
9
Boeing
BA
$177B
| – | – | 0 | – | – |
|
10
Delta Air Lines
DAL
$40.3B
| – | – | 0 | – | – |
|